ZA200209917B - Piperazinedione compounds. - Google Patents

Piperazinedione compounds. Download PDF

Info

Publication number
ZA200209917B
ZA200209917B ZA200209917A ZA200209917A ZA200209917B ZA 200209917 B ZA200209917 B ZA 200209917B ZA 200209917 A ZA200209917 A ZA 200209917A ZA 200209917 A ZA200209917 A ZA 200209917A ZA 200209917 B ZA200209917 B ZA 200209917B
Authority
ZA
South Africa
Prior art keywords
compound
dione
piperazinedione
methylidene
piperazine
Prior art date
Application number
ZA200209917A
Other languages
English (en)
Inventor
Huei-Ting Chen
Ya-Lan Chen
Yan-Bing Fan
Jih-Hwa Guh
On Lee
Eric I C Li
Che-Ming Teng
Hui-Po Wang
Original Assignee
Adpharma Inc
Teng Che Ming
Wang Hui
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adpharma Inc, Teng Che Ming, Wang Hui filed Critical Adpharma Inc
Publication of ZA200209917B publication Critical patent/ZA200209917B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Saccharide Compounds (AREA)
  • Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
ZA200209917A 2000-05-09 2002-12-06 Piperazinedione compounds. ZA200209917B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30419100P 2000-05-09 2000-05-09

Publications (1)

Publication Number Publication Date
ZA200209917B true ZA200209917B (en) 2004-04-28

Family

ID=23175471

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200209917A ZA200209917B (en) 2000-05-09 2002-12-06 Piperazinedione compounds.

Country Status (14)

Country Link
US (1) US6635649B2 (https=)
EP (1) EP1282609B1 (https=)
JP (1) JP5101781B2 (https=)
KR (1) KR100852965B1 (https=)
CN (1) CN100522949C (https=)
AT (1) ATE417614T1 (https=)
BR (1) BR0110745A (https=)
CZ (1) CZ301743B6 (https=)
DE (1) DE60137037D1 (https=)
HU (1) HUP0302358A3 (https=)
NO (1) NO326341B1 (https=)
RU (1) RU2269520C2 (https=)
WO (1) WO2001095858A2 (https=)
ZA (1) ZA200209917B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288545B2 (en) * 2000-05-09 2007-10-30 Angiorx Corporation Piperazinedione compounds
WO2002011676A2 (en) 2000-08-04 2002-02-14 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7935704B2 (en) * 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
NZ539735A (en) * 2002-10-02 2009-07-31 Dmi Biosciences Inc Diagnosis and monitoring of diseases using markers, such as diketopiperazines
EP1622633B1 (en) 2003-05-15 2016-02-24 Ampio Pharmaceuticals, Inc. Treatment of t-cell mediated diseases
US20050192348A1 (en) * 2003-09-25 2005-09-01 David Bar-Or Methods and products which utilize N-acyl-L-aspartic acid
EP1711487A1 (en) * 2004-02-04 2006-10-18 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP2300011A4 (en) 2008-05-27 2012-06-20 Dmi Life Sciences Inc THERAPEUTIC PROCESSES AND COMPOUNDS
RU2519948C2 (ru) * 2008-08-22 2014-06-20 Бритиш Коламбиа Кэнсер Эйдженси Бранч Низкомолекулярные ингибиторы n-концевой активации рецептора андрогенов
JP2012524066A (ja) * 2009-04-16 2012-10-11 テリック，インコーポレイテッド チューブリン重合阻害剤としての置換４−アミノ−５−ベンゾイル−２−（フェニルアミノ）チオフェン−３−カルボニトリルおよび置換４−アミノ−５−ベンゾイル−２−（フェニルアミノ）チオフェン−３−カルボキサミド
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
US8710062B2 (en) * 2011-03-11 2014-04-29 Taipei Medical University Piperazinedione compounds
SG10201608087WA (en) 2011-10-10 2016-11-29 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
EP3721884A1 (en) 2011-10-10 2020-10-14 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease with da-dkp (= aspartyl-alanyl diketopiperazine)
CN103841974A (zh) 2011-10-28 2014-06-04 安皮奥制药股份有限公司 鼻炎的治疗
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
JP6311097B2 (ja) * 2013-07-31 2018-04-18 学校法人東京薬科大学 微小管脱重合剤
CA2958080A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
CN104356077B (zh) * 2014-09-11 2016-09-14 中国科学院南海海洋研究所 一类不对称酰基保护的2,5-二酮哌嗪衍生物及其制备方法和应用
HK1249051A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗脑肿瘤的方法
MX383691B (es) 2015-03-06 2025-03-14 Beyondspring Pharmaceuticals Inc Método de tratamiento de cáncer asociado con una mutación de ras.
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
WO2017139231A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
RU2760348C2 (ru) 2016-06-06 2021-11-24 Бейондспринг Фармасьютикалс, Инк. Способ уменьшения нейтропении
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
CN109580801B (zh) * 2018-06-26 2021-09-07 深圳海王医药科技研究院有限公司 一种检测微管蛋白抑制剂及相关杂质的高效液相色谱法
CN112010930B (zh) * 2019-05-28 2022-08-02 首都医科大学 Rgd修饰的五环哌嗪二酮及其制备和应用
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
CN117285516A (zh) * 2022-06-16 2023-12-26 大连万众益生大健康有限公司 脱氢苯基阿夕斯汀类化合物、其制备方法及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5973574A (ja) * 1982-10-21 1984-04-25 Grelan Pharmaceut Co Ltd 環状ジペプチド類
US4806538A (en) * 1984-11-02 1989-02-21 Fujisawa Pharmaceutical Co., Ltd. Piperazine compound as PAF-antagonist
GB8609908D0 (en) * 1986-04-23 1986-05-29 Fujisawa Pharmaceutical Co Piperazine compound
DK181687A (da) * 1986-04-23 1987-10-24 Fujisawa Pharmaceutical Co Piperazinderivater og fremgangsmaade til fremstiling deraf
GB9217331D0 (en) * 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
GB9402807D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
IL112627A0 (en) * 1994-02-14 1995-05-26 Xenova Ltd Diketopiperazines, their preparation and pharmaceutical or veterinary compositions containing them
US5708804A (en) * 1994-07-25 1998-01-13 International Business Machines Corp. Apparatus and method therefor of intelligently searching for information in a personal communications device
JP3795093B2 (ja) * 1994-11-25 2006-07-12 キッセイ薬品工業株式会社 １−ヒドロキシインドール誘導体
JP3131574B2 (ja) * 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤

Also Published As

Publication number Publication date
CN1441789A (zh) 2003-09-10
CN100522949C (zh) 2009-08-05
EP1282609A2 (en) 2003-02-12
JP5101781B2 (ja) 2012-12-19
ATE417614T1 (de) 2009-01-15
US20020028819A1 (en) 2002-03-07
BR0110745A (pt) 2003-12-30
WO2001095858A2 (en) 2001-12-20
NO20025373L (no) 2002-12-13
DE60137037D1 (de) 2009-01-29
CZ301743B6 (cs) 2010-06-09
EP1282609A4 (en) 2003-06-04
JP2004510701A (ja) 2004-04-08
US6635649B2 (en) 2003-10-21
NO326341B1 (no) 2008-11-10
RU2269520C2 (ru) 2006-02-10
HUP0302358A2 (hu) 2003-11-28
WO2001095858A3 (en) 2002-03-21
KR100852965B1 (ko) 2008-08-19
CZ20023693A3 (cs) 2003-05-14
NO20025373D0 (no) 2002-11-08
EP1282609B1 (en) 2008-12-17
KR20030005336A (ko) 2003-01-17
HUP0302358A3 (en) 2007-09-28

Similar Documents

Publication Publication Date Title
US6635649B2 (en) Piperazinedione compounds
CN103237799B (zh) 杂环衍生物、制备方法及其药学用途
AU2005227954B2 (en) Heterocyclic compound and anti-malignant-tumor agent comprising the same as effective component
US7288545B2 (en) Piperazinedione compounds
US8710062B2 (en) Piperazinedione compounds
CA2216265A1 (en) Method for inhibiting the growth of mammalian cells
CN101573337A (zh) 作为抗肿瘤剂的5、6或7-取代-3-(杂)芳基-异喹啉胺衍生物
CA2408649C (en) Piperazinedione compounds
AU2001294505B2 (en) Piperazinedione compounds
US20090163494A1 (en) Protein kinase inhibitors
CN110372627A (zh) 一种1,3,4-噁二唑衍生物及其制备方法和应用
AU2001294505A1 (en) Piperazinedione compounds
AU2020320997B2 (en) Pyridine derivative as FGFR and VEGFR dual inhibitors
WO2023031246A1 (en) Substituted thiophene compounds as d-dopachrome tautomerase inhibitors
EP1270008B1 (en) Fused tricyclic analogues of guanosine for treating tumors
WO2009085040A1 (en) Protein kinase inhibitors
CA3071900A1 (en) Substituted penta- fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof
CN108276390A (zh) 一种逆转肿瘤细胞耐药的嘧啶衍生物及其应用